Summary

Global Antifungal Drugs Market was valued at approximately USD 15.88 billion in 2023 and is expected to grow at a steady compound annual growth rate (CAGR) of 3.86% over the forecast period from 2024 to 2032. Antifungal Drugs encompasses pharmaceuticals used to treat fungal infections, which can range from superficial conditions such as athlete's foot to severe systemic infections. These drugs target various fungal species, offering treatment options in the form of topical, oral, and intravenous formulations. The market is driven by the increasing prevalence of fungal infections, especially among immunocompromised individuals, coupled with the growing awareness and accessibility of antifungal treatments.

The Global Antifungal Drugs Market is driven by the rising incidence of fungal infections due to factors such as an aging population, increasing prevalence of chronic diseases, and expanding use of broad-spectrum antibiotics. The growing demand for effective treatment options in developing countries, coupled with the increasing focus on R&D for new antifungal drugs, further fuels market growth. However, the market faces restraints from drug resistance, high treatment costs, and potential side effects. Opportunities lie in the development of novel antifungal therapies, including combination treatments and biologics, as well as the growing emphasis on personalized medicine.

The key regions considered for the market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominates the anti-fungal drugs market due to its advanced healthcare infrastructure, high awareness, and substantial R&D investments. The region benefits from the presence of key market players and a large patient pool. However, the Asia-Pacific region is expected to be the fastest-growing market, driven by the increasing incidence of fungal infections, rising healthcare expenditures, and growing awareness about fungal diseases. Countries such as India and China are at the forefront of this growth, propelled by their large populations and improving healthcare access.

Major market players included in this report are:
Novartis AG
Pfizer, Inc.
Bayer AG
Sanofi
Merck & Co., Inc.
GlaxoSmithKline plc
Abbott
Glenmark
Enzon Pharmaceuticals, Inc.
Astellas Pharma, Inc.
The detailed segments and sub-segments of the market are explained below:
By Drug Class:
• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others
By Indication:
• Dermatophytosis
• Aspergillosis
• Candidiasis
• Others
By Dosage Form:
• Oral Drugs
• Ointments
• Powders
• Others
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
• RoLA
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Global Antifungal Drugs Market Executive Summary
1.1. Global Antifungal Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Indication
1.3.3. By Dosage Form
1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Antifungal Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Antifungal Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Growing Prevalence of Fungal Infections
3.1.2. Increase in Hospital-Acquired Infections
3.1.3. Advancements in Antifungal Medications
3.2. Market Challenges
3.2.1. High Costs of Treatment
3.2.2. Resistance to Antifungal Drugs
3.3. Market Opportunities
3.3.1. Expansion in Emerging Markets
3.3.2. Development of Novel Antifungal Drugs
3.3.3. Strategic Collaborations and Partnerships

Chapter 4. Global Antifungal Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Antifungal Drugs Market Size & Forecasts by Drug Class 2022-2032
5.1. Segment Dashboard
5.2. Global Antifungal Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Azoles
5.2.2. Echinocandins
5.2.3. Polyenes
5.2.4. Allylamines
5.2.5. Others

Chapter 6. Global Antifungal Drugs Market Size & Forecasts by Indication 2022-2032
6.1. Segment Dashboard
6.2. Global Antifungal Drugs Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Dermatophytosis
6.2.2. Aspergillosis
6.2.3. Candidiasis
6.2.4. Others

Chapter 7. Global Antifungal Drugs Market Size & Forecasts by Dosage Form 2022-2032
7.1. Segment Dashboard
7.2. Global Antifungal Drugs Market: Dosage Form Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Oral Drugs
7.2.2. Ointments
7.2.3. Powders
7.2.4. Others

Chapter 8. Global Antifungal Drugs Market Size & Forecasts by Distribution Channel 2022-2032
8.1. Segment Dashboard
8.2. Global Antifungal Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Others

Chapter 9. Global Antifungal Drugs Market Size & Forecasts by Region 2022-2032
9.1. North America Antifungal Drugs Market
9.1.1. U.S. Antifungal Drugs Market
9.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
9.1.1.2. Indication breakdown size & forecasts, 2022-2032
9.1.1.3. Dosage Form breakdown size & forecasts, 2022-2032
9.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032
9.1.2. Canada Antifungal Drugs Market
9.2. Europe Antifungal Drugs Market
9.2.1. U.K. Antifungal Drugs Market
9.2.2. Germany Antifungal Drugs Market
9.2.3. France Antifungal Drugs Market
9.2.4. Spain Antifungal Drugs Market
9.2.5. Italy Antifungal Drugs Market
9.2.6. Rest of Europe Antifungal Drugs Market
9.3. Asia-Pacific Antifungal Drugs Market
9.3.1. China Antifungal Drugs Market
9.3.2. India Antifungal Drugs Market
9.3.3. Japan Antifungal Drugs Market
9.3.4. Australia Antifungal Drugs Market
9.3.5. South Korea Antifungal Drugs Market
9.3.6. Rest of Asia Pacific Antifungal Drugs Market
9.4. Latin America Antifungal Drugs Market
9.4.1. Brazil Antifungal Drugs Market
9.4.2. Mexico Antifungal Drugs Market
9.4.3. Rest of Latin America Antifungal Drugs Market
9.5. Middle East & Africa Antifungal Drugs Market
9.5.1. Saudi Arabia Antifungal Drugs Market
9.5.2. South Africa Antifungal Drugs Market
9.5.3. Rest of Middle East & Africa Antifungal Drugs Market

Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Novartis AG
10.1.2. Pfizer, Inc.
10.1.3. Bayer AG
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Novartis AG
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Pfizer, Inc.
10.3.3. Bayer AG
10.3.4. Sanofi
10.3.5. Merck & Co., Inc.
10.3.6. GlaxoSmithKline plc
10.3.7. Abbott
10.3.8. Glenmark
10.3.9. Enzon Pharmaceuticals, Inc.
10.3.10. Astellas Pharma, Inc.

Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes